- IMB-202 is an inhibitor of immune check-point, overexpressed in tumor cell. It has been designed to have a dual mechanism of action to kill tumor through blocking interaction with inhibitory receptors of tumor infiltrated immune cells as well as recruiting Fc effector function.
- Binding affinity to the target antigen as well as NK cell activation ability have been much improved by grafting ePendy platform technology to antibody in research.
- We are developing IMB-202 as a revolutionary “First-in-Class” anti-cancer drug by focusing our capability.